Caplin Point Laboratories Limited — Important, 20-05-2025: Updates

Caplin Point Laboratories has announced a board meeting to consider the financial results for the quarter and half-year. Interim dividend declared at ₹3.00 per share (150%). FY25 revenue grew 15.5% to ₹2,034 Cr, with PAT rising 17.3% to ₹541 Cr. US market EBITDA jumped 71% to ₹102 Cr. Strong growth in Emerging Markets driven by new launches and asset-light outsourcing. Caplin Steriles expanded ANDA approvals to 38, with 10-12 expected in FY26. Over ₹1,000 Cr capex ongoing to boost injectables and oncology production.